Threat of drug resistant Staphylococcus aureus to health in Nepal

BMC Infectious Diseases

Moti Lal Chapagain¹  Anju Acharya¹  Goma Upadhyay¹  Sony Shrestha¹  Nabin Rayamajhi¹  Rajendra Gautam¹  Hari Prasad Nepal¹  Shamshul Ansari¹ 

[1] Department of Microbiology, Chitwan Medical College, Bharatpur, Chitwan, Nepal

关键词: Nepal;    Inducible clindamycin resistance;    MRSA;    Staphylococcus aureus;   

Others  :  1134298
DOI  :  10.1186/1471-2334-14-157

 received in 2013-05-07, accepted in 2014-03-19,  发布年份 2014

【 摘 要 】

Background

Staphylococcus aureus is the most commonly isolated organism from the different clinical samples in hospital. The emergence and dissemination of methicillin resistant Staphylococcus aureus (MRSA) and growing resistance to non-beta-lactam antibiotics is making treatment of infections due to this organism increasingly difficult.

Methods

This study was conducted to determine the frequency of Staphylococcus aureus isolated from different clinical samples, rates of MRSA and full antibiotic susceptibility profiles. Clinical samples were cultured and Staphylococcus aureus was identified using standard microbiological methods recommended by the American Society for Microbiology (ASM). Methicillin resistance was confirmed using cefoxitin and oxacillin disks. Inducible clindamycin resistance was identified using D-zone test.

Results

From the processed samples, 306 isolates of Staphylococcus aureus were recovered. All the isolates were susceptible to vancomycin and teicoplanin. Methicillin resistance was observed in 43.1% of isolates while inducible clindamycin resistance in 12.4% of the isolates.

Conclusions

The results of our study reveals that rates of resistance to commonly prescribed antibiotics in Staphylococcus aureus clinical isolates is high. In particular, rate of methicillin resistance is alarming, prompting concern on the rational use of antibiotics and vigilant laboratory-based surveillance of resistance rates in Nepal.

【 授权许可】

   
2014 Ansari et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Foster TJ: The Staphylococcus aureus “superbug”. J Clin Invest 2004, 114:1693-1696.
• [2]Lowy FD: Staphylococcus aureus infection. N England J Med 1998, 339:520-532.
• [3]Boyce JM: Epidemiology and prevention of nosocomial infections. In The staphylococci in human disease. Edited by Crossley KB, Archer GL. New York: Churchill Livingstone; 1997:309-329.
• [4]Shopsin B, Kreiswirth BN: Molecular epidemiology of methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2001, 7:323-326.
• [5]Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y: Comparison of mortality associated with methicillin resistant and methicillin sensitive Staphylococcus aureus bacteriemia: a meta analysis. Clin Infect Dis 2003, 36:53-59.
• [6]Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003, 36:592-598.
• [7]Livermore DM: Introduction: the challenge of multiresistance. Int J Antimicrob 2007, 29:51-57.
• [8]Park DW, Kim MJ, Yang JA, Jeong HW, Sohn JW, Chun BC: Risk factors for isolation of low-level mupirocin-resistant versus susceptible methicillin-resistant Staphylococcus aureus from patients in intensive care units. J Infect 2007, 54:337-342.
• [9]Manzur A, Vidal M, Pujol M, Cisnal M, Hornero A, Masuet C, Peña C, Gudiol F, Aziza J: Predictive factors of methicillin resistance among patients with Staphylococcus aureus bloodstream infections at hospital admission. J Hosp Infect 2007, 66:135-141.
• [10]Steinberg JP, Clark CC, Hackman BO: Nosocomial and community acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996, 23:255-259.
• [11]Emori TG, Gaynes RP: An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993, 6:428-442.
• [12]Deresinski S: Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005, 40:562-573.
• [13]Fluit AC, Wielders CL, Verhoef J, Schmitz FJ: Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001, 39:3727-3732.
• [14]Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS: Community acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. J American Med Assoc 1998, 279:593-598.
• [15]Salmenlinna S, Lyytikainen O, Vuopio-Varkila J: Community acquired methicillin-resistant Staphylococcus aureus, Finland. Emerging Infect Dis 2002, 8:602-607.
• [16]Mandell G, Douglas J, Bennett R: Principles and practice of infectious disease. 4th edition. Edinburgh, United Kingdome: Churchill Livingstone Ltd.; 1995.
• [17]National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testing. 7th edition. Wayne PA, USA: NCCLS; 2000. Vol. 20
• [18]HD I: Clinical microbiology procedures handbook. 2nd edition. ASM press: Washington DC; 2004.
• [19]Clinical and Laboratory Standard Institute (CLSI): Performance standards for antimicrobial susceptibility testing. Wayne, PA: USA:CLSI: M100-S16; 2006.
• [20]Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing, 17th informational supplement. Wayne, PA: USA:CLSI: M100-S17; 2007.
• [21]Smolinski MS, Hamburg MA, Lederberg J: Microbial threats to health: emergence, detection and response. Washington: Institute of Medicine; 2003. 32
• [22]Waldvogel FA: Staphylococcus aureus (including staphylococcal toxic shock). In Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 5th edition. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia, PA: CV, A Harcourt Health Sciences Co; 2000.
• [23]Tiwari HK, Das AK, Sapkota D, Sivarajan K, Pahwa VK: Methicillin resistant Staphylococcus aureus: prevalence and antibiogram in a tertiary care hospital in western Nepal. J Infect Dev Ctries 2009, 3(9):681-684.
• [24]Shakya B, Shrestha S, Mitra T: Nasal carriage rate of methicillin resistant Staphylococcus aureus among at national medical college teaching hospital, Birgunj, Nepal. Nepal Med Coll J 2010, 12(1):26-29.
• [25]Mishra SK, Rijal BP, Pokhrel BM: Emerging threat of multidrug resistant bugs-Acinetobacter calcoaceticus baumannii complex and methicillin resistant Staphylococcus aureus. BMC Research Notes 2013, 6:98-103. BioMed Central Full Text
• [26]Sanjana RK, Shah R, Chaudhary N, Singh YI: Prevalence and antimicrobial susceptibility pattern of methicillin-resistant Staphylococcus aureus (MRSA) in CMS-teaching hospital: a preliminary report. Journal of College of Medical Sciences-Nepal 2010, 6(1):1-6.
• [27]Baral R, Khanal B, Acharya A: Antimicrobial susceptibility patterns of clinical isolates of Staphylococcus aureus in Eastern Nepal. Health Renaissance 2011, 9(2):78-82.
• [28]Shrestha B, Pokhrel BM, Mohapatra TM: Antibiotic susceptibility pattern of nosocomial isolates of Staphylococcus aureus in a tertiary care hospital, Nepal. J Nepal Med Assoc 2009, 48(175):234-238.
• [29]Kumari N, Mohapatra TM, Singh YI: Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in a tertiary-care hospital in Eastern Nepal. J Nepal Med Assoc 2008, 47(170):53-56.
• [30]Sader HS, Gales AC, Jones RN: Antimicrobial activity of linezolid against gram-positive cocci isolated in Brazil. Braz J Infect Dis 2001, 5:171-176.
• [31]Cormican MG, Jones RN: Emerging resistance to antimicrobial agents in gram-positive bacteria. Drugs 1996, 51:6-12.
• [32]Shittu AO, Lin J: Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in Kwazulu-Natal province, South Africa. BMC Infect Dis 2006, 6:125-137. BioMed Central Full Text
• [33]Centers for Disease Control and Prevention: Staphylococcus aureus resistance to vancomycin in the United States of America. MMWR 2002, 51:565-567.
• [34]Classen M, Nouwe J, Fang N, Ott A, Verbrugh H, Hofman A, Vanbelkum A, Uitterlinder A: Staphylococcus aureus nasal carriage is not associated with known polymorphism in the vitamin D receptor gene. FEMS Immunol Med Microbiol 2005, 43:173-176.
• [35]Lim HS, Lee H, Roh KH, Yum JH, Yong D, Lee K, Chong Y: Prevalence of inducible clindamycin resistance in Staphylococcal isolates at a Korean tertiary care hospital. Yonsei Med J 2006, 47:480-484.
• [36]Rai CKS: Antibiotic susceptibility patters of Staphylococcus aures. J Nepal MedicalAssociation 2001, 40:138.
• [37]Subedi S, Brahmadarhan KN: Antimicrobial susceptibility pattern of clinical isolates of Staphylococcus aureus in Nepal. Clinical microbiology infect 2005, 11(3):253-237.